For many years, the western society has in case of bacterial infection very confidently relied on antibiotic treatment. Unfortunately, antibiotic resistance is now increasingly emerging and a simple scratch or hospital treatment can lead to devastating effects when infection with a so-called resistant superbug occurs.
The World Health Organization has expressed serious concerns about the emergence of antimicrobial resistance along with a steady decline in the discovery of new antimicrobials. Novel antibiotics are crucial to contain and decrease the burden of infectious diseases. This bridged PhD project will combine the target expertise of the Molecular Microbiology research group and the efficient drug discovery capabilities of the Medicinal Chemistry research group to address this need.
This bridged PhD project is part of the programmes:
Marjolein Glas MSc.